0001157523-21-000631.txt : 20210507 0001157523-21-000631.hdr.sgml : 20210507 20210507170521 ACCESSION NUMBER: 0001157523-21-000631 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210507 DATE AS OF CHANGE: 20210507 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Oxford Immunotec Global PLC CENTRAL INDEX KEY: 0001586049 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87926 FILM NUMBER: 21903809 BUSINESS ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ BUSINESS PHONE: 44 01235 442780 MAIL ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Grandeur Peak Global Advisors, LLC CENTRAL INDEX KEY: 0001569137 IRS NUMBER: 900732232 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 136 S. MAIN STREET, SUITE 720 CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: 801-384-0000 MAIL ADDRESS: STREET 1: 136 S. MAIN STREET, SUITE 720 CITY: SALT LAKE CITY STATE: UT ZIP: 84101 SC 13G 1 a52426042.htm SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934

Oxford Immunotec Global PLC
(Name of Issuer)

Common Stock
(Title of Class of Securities)
G6855A103*
(CUSIP Number)
January 31, 2021
(Date of Event which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☒   Rule 13d-1(b)
☐   Rule 13d-1(c)
☐   Rule 13d-1(d)

* CUSIP number not available.  CINS provided.

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
         
CUSIP No. G6855A103
 
13G
 
Page 2 of 5 Pages
 
 
  
 
  
         
1.
 
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Grandeur Peak Global Advisors, LLC                    90-0732232
 
 
2.
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ☐
(b)    ☐
 
 
3.
 
SEC USE ONLY
 
 
 
4.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Utah
 
 
         
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
 
5.
 
SOLE VOTING POWER
 
570,836
 
6.
 
SHARED VOTING POWER
 
-0-
 
7.
 
SOLE DISPOSITIVE POWER
 
570,836
 
8.
 
SHARED DISPOSITIVE POWER
 
-0-
         
9.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

570,836
 
 
10.
 
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ☐
 
 
11.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

2.23%
 
 
12.
 
TYPE OF REPORTING PERSON (see instructions)

IA
 
 
 
        
 

         
CUSIP No. G6855A103
 
13G
 
Page 3 of 5 Pages
 
 
  
 
  
Item 1.
 
(a)
Name of Issuer
Oxford Immunotec Global
 
    
 
(b)
Address of Issuer’s Principal Executive Offices
700 Nickerson Road, Suite 200
Marlborough, MA 01752
 
    
Item 2.
 
(a)
Name of Person Filing
Grandeur Peak Global Advisors, LLC
 
    
 
(b)
Address of the Principal Office or, if none, residence
136 South Main Street, Suite 720
Salt Lake City, UT 84101
 
    
 
(c)
Citizenship
Not Applicable
 
    
 
(d)
Title of Class of Securities
Common Stock
 
    
 
(e)
CUSIP Number
G6855A103
 
    
Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(e)  [X]   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
Item 4.  Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
         
 
(a)
 
Amount beneficially owned:  570,836
 
        
 
(b)
 
Percent of class:  2.23%
 
        
 
(c)
 
Number of shares as to which the person has:  
 
        
 
 
 
(i)
Sole power to vote or to direct the vote  570,836
 
        
 
 
 
(ii)
Shared power to vote or to direct the vote  -0-
 
        
 
 
 
(iii)
Sole power to dispose or to direct the disposition of  570,836
 
        
 
 
 
(iv)
Shared power to dispose or to direct the disposition of  -0-
 
        

Item 5.  Ownership of Five Percent or Less of a Class.
As of January 31, 2021 the beneficial interest decreased more than 5% since the previous filing.  Issuer was acquired on March 9, 2021.
Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
Not Applicable.
Item 8.  Identification and Classification of Members of the Group.
Not Applicable.
Item 9.  Notice of Dissolution of Group.
Not Applicable.
Item 10.  Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
CUSIP No. G6855A103
 
13G
 
Page 5 of 5 Pages
 
 
  
 
  
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

  5/7/2021
  Date


   /s/ Amy Hone
   Signature
   
  Amy Hone / Deputy CCO
  Name/Title